CA-CROWN-BIOSCIENCE
27.10.2020 13:02:08 CET | Business Wire | Press release
Crown Bioscience, a JSR Life Sciences company, today announces the opening of a new oncology-focused research facility in Zhongshan, China to satisfy increased customer demand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005098/en/
In addition to the Company’s four facilities across the US and Europe, CrownBio’s existing APAC footprint currently includes three sites located in Beijing, Taicang, and Suzhou, as well as one in Taiwan. Once completed, this new building will add more than 2,000m2 of new vivarium space to support CrownBio’s in vivo oncology platforms, helping satisfy predicted near-term growth.
CrownBio’s world-leading products and services are used by pharmaceutical and biotech customers across APAC, North America, and Europe to accelerate and de-risk their drug discovery programs. With the significant and continued growth of CrownBio’s client base, the Zhongshan facility has been purpose built to meet expanding study needs.
The research and drug development facility features BSL-2 laboratories and will include a state-of-the-art ABSL-2 vivarium. Initial capabilities will focus on expanding cell line-derived xenograft model availability and study throughput, with an increased roster of cutting edge, translational oncology models becoming available. Full operational capacity is expected in early 2021.
“The establishment of our new Zhongshan facility demonstrates our continued commitment to our clients, to provide sustained rapid study initiation combined with robust cost-effectiveness,” said John Gu, chief operating officer at CrownBio. “Through our growth, we can more fully support our clients in their goals of more rapid and efficient cancer drug development”.
A site opening event and ribbon cutting ceremony will take place on October 30th 2020.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
● https://www.jsrlifesciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005098/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ras Al Khaimah Ruler Awards Sheikh Saud International Prize for Materials Science at IWAM 20264.2.2026 14:09:00 CET | Press release
Prize underscores Emirate’s global commitment to science, innovation and advanced materials research His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, today awarded the Sheikh Saud International Prize for Materials Science during the 17th International Workshop on Advanced Materials (IWAM), one of the world’s leading forums for advanced materials research. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204274737/en/ HH Sheikh Saud bin Saqr Al Qasimi-keynote speech at IWAM (Photo: AETOSWire) Presented on day two of IWAM, the Prize recognizes exceptional contributions to materials science and its applications in addressing global challenges. The award was conferred upon Professor Omar Yaghi, winner of the 2025 Nobel Prize in Chemistry, in recognition of his transformative work in materials chemistry and his pioneering contributions to clean energy, carbon capture and sustai
Positron AI Raises $230 Million Series B at Over $1 Billion Valuation to Scale Energy-Efficient AI Inference4.2.2026 14:00:00 CET | Press release
Co-led by ARENA Private Wealth, Jump Trading, and Unless, with strategic investment from Qatar Investment Authority (QIA), Arm, and HelenaFunding accelerates Positron's roadmap from shipping Atlas systems today to next-generation Asimov silicon, targeting tape-out in late 2026 and production in early 2027; announced at Web Summit Qatar Positron AI, the leader in energy-efficient AI inference hardware, today announced an oversubscribed $230 million Series B financing at a post-money valuation exceeding $1 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204250472/en/ Thomas Sohmers (L), CTO and cofounder, and Mitesh Agrawal (R), CEO of Positron AI (Credit: Kavita Agrawal) The round was co-led by ARENA Private Wealth, Jump Trading, and Unless, and includes new and strategic investment from Qatar Investment Authority (QIA), Arm, and Helena. Existing investors Valor Equity Partners, Atreides Management, DFJ Growth, Res
Bridger Photonics Posts Record Year as Operators Turn to Trusted Emissions Intelligence4.2.2026 13:20:00 CET | Press release
Bridger Photonics (“Bridger”) closed its strongest year in company history last year, marked by record asset coverage, record revenue, and global adoption of its methane emissions data and intelligence across multiple continents and the entire oil and natural gas value chain. Bridger’s momentum reflects a clear shift in how operators choose to manage emissions: away from legacy and weather-limited approaches and toward entire asset coverage with data they can trust. Bridger continues to lead the methane detection space—growing existing customers and attracting new ones. Bridger has competitively displaced 32 customers from other aerial technologies, driven by deep industry expertise, proven data reliability and actionability, the ability to operate across challenging conditions and seasons, close coordination with ground crews, and a white-glove service model designed around operator needs. Customers across onshore production, midstream, LNG, and offshore operations are increasingly re
Registrar Corp Acquires TechniCAL and Becomes the Global Compliance Leader in Shelf-stable Packaged Foods Safety4.2.2026 13:00:00 CET | Press release
Registrar Corp, the world’s largest food and beverage regulatory compliance provider, today announced its acquisition of TechniCAL, the world’s leading independent Process Authority for low-acid and acidified foods. Registrar Corp is a Paine Schwartz Partners portfolio company. Consumer demand for convenience and longer product life without refrigeration has driven rapid growth in shelf-stable foods and beverages, with packaging innovations extending beyond cans and glass jars to formats such as retort pouches and cartons. Ensuring products in these various packaging formats are safe from harmful microorganisms is critical to public health and required by the U.S. FDA. Together, Registrar Corp and TechniCAL provide the industry’s most complete solution, combining proven scientific expertise, regulatory knowledge, training, and advanced thermal testing. “TechniCAL is world renowned for its Process Authority expertise and advanced testing technologies assuring compliant thermal processin
Kinaxis Announces Intention to Maximize Size of Normal Course Issuer Bid4.2.2026 13:00:00 CET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) today announces that it intends to amend its current normal course issuer bid (the “NCIB”) to increase the number of its common shares (the “Shares”) that may be repurchased from 1,403,042, representing 5% of the Company’s issued and outstanding Shares as at October 31, 2025, to approximately 2,799,843, representing 10% of the Company’s “public float” as at October 31, 2025, which is the maximum allowable under the rules of the Toronto Stock Exchange (the “TSX”). The Company has already invested US$54 million under its current NCIB. At the average price paid to date for the Shares under the current NCIB, repurchasing 10% of the Shares would represent an additional investment of approximately US$284 million. “There is a fundamental misunderstanding of the opportunities and threats from generative and agentic AI to mission-critical enterprise software, like ours, that solves deeply complex problems and enables highly consequential dec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom